Matthew A. Spear - Mar 1, 2022 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role: Chief Medical Officer
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol: PSTX
Transactions as of: Mar 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/1/2022, 06:28 PM
Previous filing: Dec 8, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+50K	+81.32%	$0.00	111K	Mar 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Award	$0	+72.6K		$0.00	72.6K	Mar 1, 2022	Common Stock	72.6K	$3.42	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2	12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.